The wearable passively measures a patient’s vital signs in real time.
Photo and thumbnail have been modified. Courtesy of Current Health.
Current Health, an artificial intelligence (AI)-powered wearable remote patient monitoring platform, has received Class II clearance from the U.S. Food and Drug Administration (FDA) for post-acute care, according to today’s press release.
The company received FDA clearance for its entire remote patient monitoring and telehealth platform. The platform includes Bluetooth integrations with other devices to track metrics.
“Patients receive a tablet equipped with a chatbot for Q&A, medication reminders and educational content, which lets patients connect with clinicians via video chat or text message to report symptoms and discuss care,” the press release said.
Current claims that with the clearance for post-acute care, it has achieved the first-ever FDA clearance for an end-to-end, real-time, passive remote patient monitoring wearable and platform.
The AI-enabled, upper-arm wearable passively measures a patient’s vital signs in real time. The device’s algorithms continuously analyze data to derive a patient’s health trajectory by detecting indicators of decline earlier for faster intervention.
“Today, Current is helping (move healthcare from hospital to home) by monitoring patients’ health trajectories to enable earlier interventions, reduce the overall and growing costs of hospital readmissions and, more importantly, prevent avoidable deaths,” said Christopher McCann, CEO and co-founder of Current Health.
With the sweeping shift in the healthcare industry to value-based care models, Current Health can aid providers in identifying at-risk patients after they leave the hospital.
Current has partnered with six large health systems in the U.S., including Mount Sinai, and several in the U.K.
In February, the FDA cleared Current Health for hospital care.
Get the best insights in digital health directly to your inbox.